During the past decade, Thomas Jefferson University Hospital - Central conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Thomas Jefferson University Hospital - Central" are "Gastric, or Gastroesophageal Junction Adenocarcinoma" (1 trials) and "Non-Small Cell Lung Cancer (NSCLC)" (1 trials). Many other conditions were trialed in "Thomas Jefferson University Hospital - Central" in a lesser frequency.

Most popular intervention types in "Thomas Jefferson University Hospital - Central" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Tislelizumab" (2 trials), "5-FU" (1 trials), "Capecitabine" (1 trials), "Cisplatin" (1 trials) and "Docetaxel" (1 trials). Other intervention names were less common.

The vast majority of trials in "Thomas Jefferson University Hospital - Central" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Thomas Jefferson University Hospital - Central". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Thomas Jefferson University Hospital - Central, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Thomas Jefferson University Hospital - Central, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".